CD274 and breast cancer: One early study with the anti-PD-L1 antibody avelumab showed an overall response rate (ORR) of only 4.8% in breast cancer patients; however, patients prescreened for PD-L1 expression in a different study had an ORR that reached 21.4%4,5.